Ra Capital Management, L.P. Phathom Pharmaceuticals, Inc. Transaction History

Ra Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$11.55 - $20.06 $36 Million - $62.5 Million	-3,115,008 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $24 Million - $34.6 Million	-710,000 Reduced 18.56%	3,115,008 $117 Million
Q2 2020 Aug 14, 2020	BUY	$25.06 - $54.6 $2.95 Million - $6.42 Million	117,600 Added 3.17%	3,825,008 $126 Million
Q1 2020 May 15, 2020	BUY	$24.65 - $42.83 $1.49 Million - $2.6 Million	60,600 Added 1.66%	3,707,408 $95.7 Million
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $67.8 Million - $137 Million	3,646,808 New	3,646,808 $114 Million

143

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $266M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.